Kentucky SB82 prohibits certain boards from restricting medications for substance use disorder.
Kentucky SB82 creates new sections in the Kentucky Revised Statutes to prevent the State Board of Medical Licensure, the Kentucky Board of Dentistry, the Kentucky Board of Pharmacy, and the Kentucky Board of Nursing from restricting or limiting the prescribing, dispensing, or administering of buprenorphine-mono-product, buprenorphine-combined-with-naloxone, or any other Schedule III, IV, or V medication approved by the United States Food and Drug Administration for the treatment of a substance use disorder. The bill declares an emergency and takes effect upon passage and approval.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.